Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 3/20 | 0.52 |
| ▸ | CES1 | P23141 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 4/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1552000 | 0.83 | ESR1 (0.38) | CES2CES1LMNATSHRL3MBTL1 | |
| SCHEMBL6002650 | 0.81 | CES2 (0.52) | CES2CES1LMNATSHRMAPK1 | |
| SCHEMBL6448217 | 0.79 | TSHR (0.55) | CES2CES1LMNATSHRMAPK1 | |
| SCHEMBL7555313 | 0.79 | TSHR (0.55) | CES2CES1LMNATSHRMAPK1 | |
| SCHEMBL11608886 | 0.77 | CES2 (0.48) | CES2CES1LMNATSHRMAPK1 | |
| SCHEMBL7959261 | 0.77 | CES2 (0.48) | CES2CES1LMNATSHRMAPK1 | |
| SCHEMBL28879993 | 0.77 | ALDH1A1 (0.48) | CES2CES1LMNATSHRMAPK1 | |
| SCHEMBL75640 | 0.77 | MAPT (0.69) | CES2CES1LMNATSHRMAPK1 | |
| SCHEMBL17187946 | 0.77 | MAPT (0.69) | CES2CES1LMNATSHRMAPK1 | |
| SCHEMBL190531 | 0.77 | CES2 (0.50) | CES2CES1LMNATSHRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 165 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3089980-B1 | SERINE/THREONINE KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2018-01-31 | — | — | EP | claimed |
| US-9670208-B2 | Serine/threonine kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2017-06-06 | — | — | US | claimed |
| EP-3089980-A1 | SERINE/THREONINE KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2016-11-09 | — | — | EP | claimed |
| US-20160304519-A1 | SERINE/THREONINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2016-10-20 | — | — | US | claimed |
| WO-2015103137-A1 | SERINE/THREONINE KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2015-07-09 | — | — | WO | claimed |
| US-8183239-B2 | Substituted piperazines and piperidines as modulators of the neuropeptide Y2 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2012-05-22 | — | — | US | claimed |
| US-20100298392-A1 | Isoindoline Derivatives For The Treatment Of Arrhythmias | ASTRAZENECA AB (SE) | 2010-11-25 | — | — | US | claimed |
| CN-101528690-A | Isoindoline derivatives for the treatment of arrhythmias | ASTRAZENECA AB (SE) | 2009-09-09 | — | — | CN | claimed |
| CN-101490002-A | 3-oxoisoindoline-1-carboxamide derivatives as analgesic agents | ASTRAZENECA AB (SE) | 2009-07-22 | — | — | CN | claimed |
| EP-1802293-A4 | ORALLY EFFECTIVE CANNABINOID ANALOGS | PHARMOS CORP (US) | 2009-04-29 | — | — | EP | claimed |
| WO-2007053436-A1 | SUBSTITUTED PIPERAZINES AND PIPERIDINES AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-10 | — | — | WO | claimed |
| US-20070100141-A1 | SUBSTITUTED PIPERAZINES AND PIPERIDINES AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-05-03 | — | — | US | claimed |
| WO-2006043260-A2 | ORALLY EFFECTIVE CANNABINOID ANALOGS | PHARMOS CORPORATION (US) | 2006-04-27 | — | — | WO | claimed |
| EP-1469842-A4 | BICYCLIC CB2 CANNABINOID RECEPTOR LIGANDS | PHARMOS CORP (US) | 2006-04-26 | — | — | EP | claimed |
| JP-2005523259-A | — | — | 2005-08-04 | — | — | JP | claimed |
| US-20050020544-A1 | Bicyclic CB2 cannabinoid receptor ligands | PHARMOS CORPORATION | 2005-01-27 | — | — | US | claimed |
| EP-1469842-A2 | BICYCLIC CB2 CANNABINOID RECEPTOR LIGANDS | PHARMOS CORPORATION (US) | 2004-10-27 | — | — | EP | claimed |
| WO-2003063758-A2 | BICYCLIC CB2 CANNABINOID RECEPTOR LIGANDS | PHARMOS CORPORATION (US) | 2003-08-07 | — | — | WO | claimed |
| EP-0190096-B1 | PROCESS FOR THE PROTECTION OF KERATIN-CONTAINING MATERIAL AGAINST ATTACK BY KERATIN PESTS, AND ESTERS | CIBA-GEIGY AG (CH) | 1989-08-16 | — | — | EP | claimed |
| EP-0125093-A1 | Diaz(ep)ine bis(N-amidinoamidine) derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1984-11-14 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070100141-A1 | SUBSTITUTED PIPERAZINES AND PIPERIDINES AS MODULATORS OF THE NEUROPEPTIDE Y2 RECEPTOR | NPY2R, NPY5R, NPY4R | CES2 2729/4885CES1 4115/4885LMNA 3057/4885 |
| US-20050020544-A1 | Bicyclic CB2 cannabinoid receptor ligands | CNR1, CNR2, CHRNE | CES2 960/4885CES1 404/4885LMNA 721/4885 |
| US-20160304519-A1 | SERINE/THREONINE KINASE INHIBITORS | TTBK1, MAP3K1, TNNI3K | CES2 4081/4885CES1 2173/4885LMNA 1573/4885 |
| US-20100298392-A1 | Isoindoline Derivatives For The Treatment Of Arrhythmias | KCNH1, KCNH2, KCNQ2 | CES2 1721/4885CES1 2196/4885LMNA 461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.